RxDoctor Payments Data

Mark Nathan

Interventional Cardiology · Walnut Creek, CANPI 1013947670

Payments from drug & device makers

$173,471in general payments, 2019–2025

Across 218 payments — averaging $795.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$83K
  • Lilly USA, LLC$39K
  • Astellas Pharma US Inc$20K
  • Boehringer Ingelheim International GmbH$9K
  • Amgen$7K
  • AstraZeneca$7K
  • plus $10K from 12 others

What the payments were for

  • Consulting fees$5,4003%
  • Speaking & faculty fees$127,70981%
  • Travel & lodging$20,03913%
  • Food & beverage$4,9873%
  • Education$1100%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,471 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Other interventional cardiology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →